ArticleFrontiers in immunology2020
Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- A multivalent subunit vaccine augments pre-existing immunity to protect against T3SS-positiveInfection and immunity · 2026Article
- Effectiveness and immunogenicity of a nanoemulsion protein subunit vaccine against Pseudomonas aeruginosa: investigation in diet-induced obese mice.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Live auxotrophic vaccines contribute to protection against chronic lung infections caused byFrontiers in immunology · 2026Article
- Comparative immunogenicity and protective efficacy of BECC438 and BECC470 adjuvants in a vaccine formulation againstFrontiers in immunology · 2026Article
- A high-throughput multi-species platform using Biolayer Interferometry Immunosorbent Assay (BLI-ISA) as an alternative to indirect ELISA for vaccine development.Journal of immunological methods · 2025Article
- Chimeric Fimbrial Multiepitope Antigen Fused to Double-Mutant LT (dmLT) Induces Antibodies That Inhibit EnterotoxigenicAnimals : an open access journal from MDPI · 2025Article
- Development of a bivalent protein subunit vaccine against infection by Pseudomonas aeruginosa and Staphylococcus aureus.NPJ vaccines · 2025Article
- Review
- Beyond pathogenicity: applications of the type III secretion system (T3SS) ofFrontiers in microbiology · 2025Review
- Development of a nano-emulsion based multivalent protein subunit vaccine againstFrontiers in immunology · 2024Article
- Development of innovative multi-epitope mRNA vaccine against Pseudomonas aeruginosa using in silico approaches.Briefings in bioinformatics · 2023Article
- A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection.NPJ vaccines · 2023Article
- Immunogenicity and protective efficacy of nanoparticle formulations of L-SseB againstFrontiers in immunology · 2023Article
- Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice.Infection and immunity · 2022Article
- Review
- Nontypeable Haemophilus influenzae Infection Impedes Pseudomonas aeruginosa Colonization and Persistence in Mouse Respiratory Tract.Infection and immunity · 2022Article
- Vaccination of mice with hybrid protein containing Exotoxin S and PcrV with adjuvants alum and MPL protects Pseudomonas aeruginosa infections.Scientific reports · 2022Article
- Vaccination to PreventFrontiers in microbiology · 2022Article
- Pseudomonas aeruginosa Antivirulence Strategies: Targeting the Type III Secretion System.Advances in experimental medicine and biology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Sayan DasDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, United States.
Debaki R HowladerDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, United States.
Qi ZhengDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, United States.
Siva Sai Kumar RatnakaramDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, United States.
Sean K WhittierDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, United States.
Ti LuDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, United States.
Johnathan D KeithDepartment of Medicine and Gregory Fleming James Cystic Fibrosis Research Center, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
William D PickingDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, United States.
Susan E BirketDepartment of Medicine and Gregory Fleming James Cystic Fibrosis Research Center, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Wendy L PickingDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, United States.
University of Kansas · USUniversity of Alabama at Birmingham · US
Funding
UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Brian R. Davis · 2007 to 2026
$23.0MVaccines to counter emerging antibiotic resistance (R01AI138970)R01AI138970 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI PICKING, WENDY L. · 2018 to 2022
$6.0MDevelopment of a broadly protective subunit vaccine against Pseudomonas aeruginosaR21AI140701 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI PICKING, WENDY L. · 2018 to 2019
$427kNIAID NIH HHS R01 AI138970NIAID NIH HHS R21 AI140701NIDDK NIH HHS P30 DK072482
Abstract
Infections caused by the opportunistic pathogen
Indexed as
Adjuvants, ImmunologicAnimalsAntibodies, BacterialAntigens, BacterialBacterial ToxinsBacterial VaccinesBroadly Neutralizing AntibodiesDendritic CellsDisease Models, AnimalHumansImmunity, HumoralMiceMice, Inbred BALB CPneumoniaPore Forming Cytotoxic ProteinsPseudomonas aeruginosaAdjuvants, ImmunologicAntibodies, BacterialAntigens, Bacterialantigen V, PseudomonasBacterial ToxinsBacterial VaccinesBroadly Neutralizing AntibodiesPore Forming Cytotoxic ProteinsRecombinant Fusion ProteinsType III Secretion SystemsVaccines, SubunitIL-17opsonophagocytosisPcrVPopBprotective efficacyPseudomonas aeruginosatype III secretion systemvaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.